Despite the aforementioned emerging uses of CGP, at present, data to support therapeutic recommendations for many targeted drugs is not robust enough to warrant therapy off a clinical trial, e.g., trastuzumab in (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2) ERBB2 amplified lung cancer. This evidence concerns the gene ERBB2 and lung cancer.